In a significant advancement for prostate cancer research, a first-of-its-kind study led by Emory researchers uncovered how ...

Consequently, research has hypothesized that blocking GP130, thereby disrupting the associated signaling pathway, would inhibit STAT3 activity and, in turn, suppress cancer growth. Surprisingly ...

Prostate cancer is the second most common cancer in men worldwide. ... tumor growth can be slowed down not by inhibiting but by activating the GP130 signaling pathway in prostate cells.

Researchers identified SDR42E1 as a key regulator of vitamin D absorption and sterol metabolism in colorectal cancer cells.

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD)..

Prostate cancer tumor biology can differ significantly based on whether a patient is Black or white, according to data from a ...

Cite this: Add-On Niraparib May Slow Hormone-Sensitive Metastatic Prostate Cancer - Medscape - June 09, 2025. Comments Commenting is limited to medical professionals.

Proposed roles of active IL6ST signaling in prostate tumorigenesis. Credit: Molecular Cancer (2024). DOI: 10.1186/s12943-024-02114-8 ...

Consequently, research has hypothesized that blocking GP130, thereby disrupting the associated signaling pathway, would inhibit STAT3 activity and, in turn, suppress cancer growth. Surprisingly ...